We are live on ! Find out more

Veradermics Inc

MANE

Market cap $5.71B

129.66 USD

-5.63

4.16%

At close Updated Nov 13, 4:00 PM EST

Pre-market

After hours

128.30

-1.36

1.05%

1 day

-4.16%

5 days

-6.08%

1 month

11.53%

3 months

16.81%

6 months

21.02%

Year to date

243.47%

1 year

243.47%

5 years

243.47%

10 years

243.47%

About: Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

Employees: 21

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 28.6%

Neutral 71.4%

Negative 0%

Veradermics to Present at the Jefferies Global Healthcare Conference in London

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will present at the Jefferies Global Healthcare Conference in London on Thursday, November 19, 2026, at 8:30 a.m. GMT / 3:30 a.m. EST. A live webcast of the presentation will be available on the “Events” page of the “Investors” section of the Company's.

Veradermics to Present at the Jefferies Global Healthcare Conference in London

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent corporate and clinical progress. “This has been a defining year for Veradermics as we advanced the development of VDPHL01 as a potential treatment for pattern hair loss in both men and wome.

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript

Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript

Veradermics, Incorporated (MANE) Discusses Positive Study 302 Part B Results for VDPHL01 in Pattern Hair Loss Transcript

Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from Part B of its randomized, double-blind, placebo-controlled, registration-directed Phase 2/3 clinical trial (Study ‘302') evaluating VDPHL01, an investigational, proprietary, extended-release oral minoxidil formulation, in over 500 males with mild-.

Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss

Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, November 9, 2026, at 8:00 am ET to review topline results from Part B of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘302') evaluating VDPHL01, a proprietary, ext.

Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302' Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript

Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript

Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss Transcript

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Veradermics NYSE: MANE reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern hair loss.

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results

Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Monday.

Silence Therapeutics, Disc Medicine, Veradermics And Other Big Stocks Moving Higher On Monday

Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study

Drug developer Veradermics said on Monday that its oral pill helped increase hair growth in men with pattern hair loss in a ‌late-stage study.

Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study

Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304' Clinical Trial in Male Pattern Hair Loss

NEW HAVEN, Conn.--(BUSINESS WIRE)--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from Part A of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘304') evaluating VDPHL01, a proprietary, extended-release oral minoxidil formulation, in over 500 males with mild-to-moderate pattern h.

Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304' Clinical Trial in Male Pattern Hair Loss

See News Rankings

Price charts implemented using Lightweight Charts™